Last reviewed · How we verify

NCT04083118: AoRTAS

Assessment of Risk in Thoracic Aortopathy Using 18F-Sodium Fluoride

Completed Last updated 29 November 2023
What this trial tests

trial testing clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI in Bicuspid Aortic Valve in 95 participants. Completed in 3 September 2023.

Timeline
1 April 2019
Primary endpoint
3 September 2023
3 September 2023

Quick facts

Lead sponsorUniversity of Edinburgh
StatusCompleted
Study typeOBSERVATIONAL
Enrollment95
Start date1 April 2019
Primary completion3 September 2023
Estimated completion3 September 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Edinburgh

Who can join

Adults 20 to 100, any sex, with Bicuspid Aortic Valve or Thoracic Aortic Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with bicuspid aortic valve-related aortopathy are at increased risk of aortic dilatation, dissection and rupture. Currently, risk stratification is largely based on aortic diameter measurements, with those deemed high risk referred for aortic replacement surgery. This approach is imperfect, and potentially exposes many patients to unnecessary high-risk aortic surgery, or fails to identify those at risk of dissection or rupture with smaller diameters. In patients with abdominal aortic aneurysms, the investigators recently demonstrated that uptake of 18F-sodium fluoride predicts disease progression and clinical events independent of aneurysm diameter and standard clinical risk factors. Based on the investigators preliminary data, a study was proposed to look at 18F-sodium fluoride uptake in patients with bicuspid aortic valve-related aortopathy. The proposed study will shed light on the underlying pathological processes involved in aortic complications of this disease as well as potentially providing an important risk marker to predict disease progression and guide the need for major aortic surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Microcalcification and Thoracic Aortopathy: A Window Into Disease Severity.
    Fletcher AJ, Nash J, Syed MBJ, Macaskill MG, et al · · 2022 · cited 14× · PMID 35770666 · DOI 10.1161/atvbaha.122.317111
  2. Molecular Calcification Imaging and Ascending Aortic Disease in Patients With a Bicuspid Aortic Valve.
    Nash J, Debono S, Loganath K, Whittington B, et al · · 2026 · PMID 41729522 · DOI 10.1001/jamanetworkopen.2025.60385
  3. Thoracic aortic microcalcification activity in combined positron emission tomography and magnetic resonance imaging.
    Nash J, Debono S, Whittington B, Kaczynski J, et al · · 2024 · PMID 38456972 · DOI 10.1007/s00259-024-06670-5

Verify or expand the search:

Other recruiting trials for Bicuspid Aortic Valve

Currently open trials in the same condition.

Other University of Edinburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04083118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing